Non-invasive prenatal testing (NIPT) is a sophisticated method used for the screening of chromosomal abnormalities developing in the fetus. Currently, NIPT is considered a valuable test for the pregnant women to provide cost-effective and highly efficient early diagnosis of genetic disorders. The growth in the market is attributed to the increasing reimbursement policies and insurance coverage across the globe. Further, the continued significant investments for genome sequencing by healthcare companies to meet the industry demand and the growing incidence of genetic disorders are the prominent factors propelling the growth of the global NIPT market. Non-invasive prenatal market was valued at $2.52 billion in 2020 and is expected to reach $12.61 billion by 2031.



